REG - Ondine Biomedical - Exercise of Options

Ondine BiomedicalAnnouncement

10/06/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250610:nRSJ0650Ma&default-theme=true

RNS Number : 0650M  Ondine Biomedical Inc.  10 June 2025

10 June 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

Exercise of Options

Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company pioneering
light-activated antimicrobial treatments, announces that it has received
notices of exercise in respect of options to subscribe for 200,000 new
ordinary shares of no par value each in the capital of the Company ("Ordinary
Shares") (the "Option Shares") at an exercise price of CA$0.01 per
Option Share.

Application has been made for the Option Shares, which will rank pari
passu with the Company's existing Ordinary Shares, to be admitted to trading
on AIM ("Admission"). It is expected that Admission will become effective and
that dealings in the Option Shares will commence on or around AIM at 8.00 a.m.
on 13 June 2025. Following Admission, the Company's total issued share capital
will consist of 443,433,174 Ordinary Shares. As the Company does not hold any
shares in Treasury, this figure may be used by shareholders in the Company as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
share capital of the Company following Admission.

 

Enquiries, please contact:

 Ondine Biomedical Inc.                                     www.ondinebio.com (https://ondinebio.com/)
 Carolyn Cross, CEO
Via Vane Percy & Roberts
 Strand Hanson Limited (Nominated & Financial Adviser)       +44 (0)20 7409 3494

James Harris, Richard Johnson
 RBC Capital Markets (Broker)                                +44 (0)20 7653 4000

Kathryn Deegan
 Vane Percy & Roberts (Media Contact)                       +44 (0)77 1000 5910
 Simon Vane Percy

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is
approved in Canada, Australia, Mexico and several other countries under the
name Steriwave®. In the US, it has been granted Qualified Infectious Disease
Product designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEBUGDLRGGDGUC